VER since William Harvey described the circulation of the blood, physiologists have realized that, "in sound and living vessels the blood remains fluid, but it coagulates in dead ones" (Ernst Briicke, 1857).
• The vascular endothelium, which envelops the circulating blood in a continuous monolayer, is mainly responsible for this function as well as for the maintenance of the integrity and patency of vessels. These properties of endothelial cells have been linked with their capacity to synthesize a large number of active substances such as prostacyclin, 2 13-hydroxy-9,l 1-octadecadienoic acid (13-HODE), 3 15-hydroxy-5,8,ll,13-eicosatetraenoic acid (15-HETE), 4 endothelium-derived relaxing factor (EDRF), 5 von Willebrand factor, 6 tissue-type plasminogen activator (t-PA), 7 t-PA inhibitors, 8 growthpromoting factors, 9 platelet-activating factor (1-alkyl-2-acetyl-jn-glycero-3-phosphocholine), 10 mucopolysaccharides, 11 type IV collagen, 12 a wide range of antioxidant enzymes, 13 and others. An altered ability of the endothelial cells to make some of these factors (such as prostacyclin and EDRF) has been associated with cardiovascular diseases, including hypertension and atherosclerosis. A potent vasoconstrictor peptide, endothelin, has also recently been discovered, characterized, and synthesized. 14 The production schedule of this complex biochemical factory is modulated by the interaction of the endothelium with blood cells or with plasma constituents in the vessel lumen and by the metabolic and functional state of the basement membrane and smooth muscle cells outside the endothelial lining. For instance, procedures that stimulate the generation of prostacyclin include the transfer of prostaglandin endoperoxides from platelets, 15 -16 or contact with activated leukocytes, 17 or an increase in plasma levels of vasoactive peptides, 18 or damage to or distention of the arterial wall. Some metabolic functions of the endothelium (especially seen in the pulmonary endothelium), such as conversion of angiotensin I to angiotensin II or inactivation of bradykinin and nucleotides, or taking up and metabolizing 5-hydroxytryptamine, catecholamines, and acetylcholine, 19 -20 have also been associated with the concomitant secretion of prostacyclin 18 - 21 or EDRF
-

21
-n (or both). Finally, oxygen tension in tissues 5 - 13 has a strong influence on the biological functions of the endothelium; for example, hypoxia increases the levels of messenger RNA for endothelin production. 14 Such a complexity of systems makes it difficult to relate the importance of each of them to endothelial regulatory function. Three components will be reviewed here: prostacyclin, lipoxygenase products, and EDRF. All these products are more or less labile, and their generation, inactivation, and mechanism of action seem to be connected with the biological activities of oxygen free radicals.
Prostacyclin
The discoveries of thromboxane A 2 (made by platelets) and of prostacyclin (made by the vessel wall) have led to many important new concepts in vascular pathophysiology. 24 Prostacyclin is a dienoic bicyclic eicosanoid that derives from the membrane-bound fatty acid, all-cis 5,8,11,14-eicosatetraenoic acid (arachidonic acid, AA). The chemical instability of prostacyclin at physiological pH (tYi ~3 minutes) is a result of the cleavage of its furan ring with subsequent formation of 6-keto-prostaglandin F to (6-keto-PGF,J. Unlike prostacyclin, 6-keto-PGF la and the products of its enzymic metabolism, such as 6,15-diketo-PGF la , 13,14-dihydro-6-keto-PGF, a , and dinor-6-keto-PGF, a , are chemically stable and have little or none of the biological actions of prostacyclin.
-
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An exception is 6-keto-PGE,, which is a stable compound exhibiting many of the properties of prostacyclin, 27 ' M although usually it is less potent. However, in causing renin release 28 or fibrinolysis, 29 it is more active. The possible importance of 6-keto-PGE, stems from the claim that, in vitro, prostacyclin is transformed to 6-keto-PGE, by the action of 9-hydroxydehydrogenase 27 from broken cell preparations, such as those of kidneys, 6 -9 platelets, 17 and blood cells. 30 - 31 6-Keto-PGF, a is not a substrate for the enzyme in homogenates of dog brain, cultured endothelial cells, or fibroblasts.'• - 12 There is some dispute as to whether whole platelets can generate 6-keto-PGE, from prostacyclin. 32 Formation of 6-keto-PGE, has also been observed in isolated organs, such as the rabbit liver 27 and rat lungs perfused with salt solutions. 33 There are difficulties in accepting that 6-keto-PGE, is an important member of the endogenous prostaglandin family. First, it has not always been rigorously identified. Second, most of the work has been in vitro, and third, its plasma levels did not increase after the intravenous infusion of prostacyclin.
34
Biosynthesis of Prostacyclin
The biosynthesis of prostacyclin by endothelial cells is initiated either through a transmembrane transference of prostaglandin endoperoxides from platelets 15 - 16 or by intracellular generation from AA, which is liberated from endothelial phospholipids by an activated phospholipase (Figure 1 ). For instance, release of prostacyclin from porcine endothelial cells by bradykinin is accompanied by activation of both phospholipase A 2 and phospholipase C. 33 -% The latter leads to rapid production of inositol triphosphate with a subsequent mobilization of cytosolic Ca 2+ and liberation of AA. In addition, the stimulation of prostacyclin formation by adenosine 5'-triphosphate (ATP) is secondary to ATP-induced inositol phospholipid metabolism in adrenal medullary endothelial cells.
37
A heme-containing oxygenase (cyclooxygenase) that requires no external source of electrons both cyclizes AA and adds the 15-hydroperoxy group to form PGG 2 . The hydroperoxy group of PGG 2 is reduced to the hydroxy group of PGH 2 by a peroxidase that utilizes a wide variety of compounds to provide the requisite pair of electrons. Both enzymes are contained in a single 71-kilodalton protein.
38
Cyclooxygenase is inhibited by aspirin and aspirinlike drugs, 39 -40 and its action is modulated by lipid hydroperoxides, including PGG 2 . 41 PGG 2 peroxidase (sometimes called PGH 2 synthase), which is a part of the cyclooxygenase complex, can adjust the overall yield of the enzyme. This and other peroxidases maintain the concentrations of lipid peroxides that determine the activity of both cyclooxygenase 41 and prostacyclin syn- 
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HYPERTENSION VOL 12, No 6, DECEMBER 1988 thase. 42 The activity of cyclooxygenase is stimulated by lipid hydroperoxides at low concentrations (10~l 0 -l(T 7 M) and inhibited by higher concentrations (>1(T 6 M; Figure 2 ). Salicylate, aspirin, and indomethacin have been reported to inhibit 12-hydroperoxyeicosatetraenoic acid (HPETE) peroxidase, 43 but this has not been confirmed. 44 Other cyclooxygenase inhibitors may also influence peroxidase activity in parallel with their main mechanism of action, perhaps leading to a further suppression of prostaglandin biosynthesis.
38
The reduction of hydroperoxy-lipids to hydroxylipids is associated with the generation of oxygen free radicals, 45 most likely hydroxyl radicals. 46 It may well be that inhibition of the isomerization of PGH 2 to prostacyclin by lipid hydroperoxides 42 -47 and by other organic hydroperoxides 48 is mediated by the oxygen free radicals that arise as a result of the decomposition of these hydroperoxides. 49 Endothelial cells in culture spontaneously generate superoxide anion (O 2~) 50 as well as when they are treated with interleukin 1, -y-interferon, phorbol myristate acetate, calcium ionophore A23187, 51 -52 or menadione. 53 This O 2~ may serve as an alternative source of hydroxyl radicals, 47 which have been postulated to be endogenous inhibitors of prostacyclin synthase.
Any potential intracellular activity of oxygen free radicals is reduced by the antioxidant enzymes of endothelial cells 13 56 is in keeping with the association between decreased prostacyclin biosynthetic capacity in arteries of animals fed an atherogenic 56 or vitamin E-deficient 57 -58 diet and increased aortic 57 or plasma 56 levels of lipid hydroperoxides. The supplementation of either diet with vitamin E partially corrects the abnormalities in prostacyclin and lipid hydroperoxide metabolism. 57 -59 If uncorrected, both diets lead to damage of the vascular wall.
In discussing lipid peroxidation, it is interesting to note that a substantial body of literature connects the peroxidase activity of cyclooxygenase with the formation of potential carcinogens, through a mechanism of cooxidation. This has been reviewed by Boyd and Eling 60 and Mamett. 61 Cooxidation of AA and, for instance, amino acids or secondary amines could have relevance to the coupling of the generation of prostacyclin with that of EDRF (see later).
Substances That Release Prostacyclin
Several drugs, as well as endogenous mediators, stimulate the generation of prostacyclin by cultured endothelial cells or smooth muscle cells. Before accepting a substance as a potentially important stimulator of prostaglandin synthesis, it is prudent to confirm its activity in more than one experimental system. Endogenous substances leading to the generation of prostacyclin, which work in several systems, include bradykinin, 21 70 may also be generated by endothelial cells.
The role of these endogenous substances in generating prostacyclin in vivo is uncertain. Bradykinin and choline esters may have the strongest case, for they are potent and release prostacyclin from endothelial cells into the culture medium 21 -62 and from tissues into the blood stream of humans 63 and animals. 18 Other vasoactive peptides, such as angiotensin I and angiotensin II, which release prostacyclin from perfused lungs 71 and blood vessels of anesthetized cats, 18 are not good candidates as endogenous regulators of the release of prostacyclin. In cats, the release of prostacyclin by angiotensin I is blocked by captopril (an inhibitor of angiotensin converting enzyme). However, in humans, captopril induces an elevation of plasma levels of 6-keto-PGF,,,, 72 in line with the assumption that inhibition of ACE also prevents the breakdown of bradykinin, a known prostacyclin generator. 21 18 also stimulate the formation of prostacyclin in vivo, since they enhance the transference of PGH 2 from platelets to the vascular endothelium. 15 -16 Pulsatile pressure also induces the release of prostacyclin in isolated arteries, 77 ' n leading to the suggestion that this is a stimulus for a continuous basal release. However, circulating concentrations of 6-keto-PGF la are very low in humans, 79 as are the normal urinary metabolites. 80 One interpretation of this result is that the prostacyclin defense mechanism is only called into play at the site of injury to a vessel. Certainly, as with other prostaglandins, 81 prostacyclin release is increased by damage to cells.
Inhibitors of Prostacyclin Release
Glucocorticosteroids and lipocortin, 82 -83 cyclooxygenase inhibitors, 21 low density lipoproteins 84 loaded with lipid hydroperoxides, 85 and, unexpectedly, vitamin K, 86 all inhibit the biosynthesis of prostacyclin in endothelial cells. As mentioned earlier, vitamin K 3 (menadione) stimulates the generation of O 2~ in cultured endothelial cells. 49 Low density lipoproteins contain oxidized lipids 84 -M that can generate oxygen free radicals, which may also inhibit the synthesis of prostacyclin by endothelial cells. It has been suggested that oxygen free radicals generated during the biosynthesis of prostaglandins 45 ' <* are responsible for arteriolar damage following brain injury. 87 Exposure of cultured endothelial cells to ozone also reduced the synthesis of prostacyclin.
88
Like glucocorticosteroids 83 and unlike 17/3-estradiol, testosterone 89 impedes the biosynthesis of prostacyclin in vascular cells. This might contribute to the higher risk of cardiovascular accidents seen in men than in women.
The capacity of vascular tissue to generate prostacyclin decreases in old 90 and in atherosclerotic 56 -9I animals. Indeed, it has been postulated 56 -w that there is a direct link between the ability of the vascular wall to synthesize prostacyclin and its susceptibility to thrombotic or atherosclerotic episodes. Paradoxically, excretion of prostacyclin metabolites by patients with severe atherosclerosis exceeded that by healthy volunteers, 93 and synthesis of prostacyclin was actually increased in atherosclerotic rabbits. 94 Vascular biosynthesis of prostacyclin does not seem to play a major role in the pathogenesis of hypertension. Hypertensive, salt-sensitive Dahl rats 95 or patients with essential hypertension 96 had abnormally high rates of synthesis, whereas spontaneously hypertensive rats either had low prostacyclin levels 97 or showed no difference from normal.
98
Prostacyclin synthesis can be low at the time immediately preceding development of hypertension, 99 and this may contribute to its progress. 100 The accelerated synthesis that parallels raised blood pressure may therefore be a compensatory adaptive mechanism in response to the hypertensive state.
Actions of Prostacyclin
The platelet-suppressant and vasodilator actions of prostacyclin 24 -"• *> are mediated by the stimulation of adenylate cyclase in platelets 101 and in vascular smooth muscle. 102 In intact endothelial cells, prostacyclin also increases cyclic adenosine 3',5'-monophosphate (cAMP) levels, an effect that might influence the proliferation, permeability, and contractility of the endothelial lining.
103
The link between prostanoids and cyclic nucleotides in the vascular wall is extended by their activity on the enzymes that catalyze the metabolism of cholesteryl esters. Prostacyclin and 6-keto-PGE! both increase cAMP levels in vascular smooth muscle, and, in parallel, these prostanoids enhance the activity of acid cholesteryl ester hydrolase, though they do not influence the activity of acyl-CoA/cholesterol O-acyl-transferase (EC 2.3.1.26). The latter, incidentally, is inhibited by PGEj. Thus, the combined actions of prostacyclin and PGE 2 will trigger an outflow of free cholesterol from endothelial cells. This process is facilitated by the extracellular presence of a sterol carrier protein (e.g., high density lipoprotein apoproteins).
104 It could well be that, in vivo, the prostacyclin and/or PGE 2 generating system is responsible for clearing cholesteryl esters off the vascular wall, whereas an inhibition of cyclooxygenase and/or prostacyclin synthase by lipid hydroperoxides 4155105 brings about an accumulation of cholesteryl esters in the vascular wall, formation of foam cells, and atherogenesis.
Recently, Willis et al. 106 -107 found that prostacyclin and its analogues suppress the accumulation of cholesterol esters by macrophages and also suppress the release of growth factors from endothelial cells, macrophages, and platelets. The latter effect is seen at concentrations that are one tenth of those required to inhibit platelet aggregation. Indeed, prostacyclin inhibits release of platelet-derived growth factor from platelet a granules in preference to /3-thromboglobulin and platelet factor 4. In addition, a decrease in the lipid content of vascular wall cells has been seen in humans after prostacyclin infusion. A VOL 12, No 6, DECEMBER 1988 contribution to this effect could come from increased metabolism of cholesterol esters by smooth muscle cells under the influence of prostacyclin.
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The fibrinolytic and cytoprotective properties of prostacyclin do not seem to be mediated by cAMP, and yet their impact on the therapeutic prospects of prostacyclin and its analogues is noteworthy. 30 The first observation on the thrombolytic action of prostacyclin in dogs with pulmonary thromboembolism 109 was followed by reports of shortening of the euglobulin clot lysis time in patients who had been treated with a continuous intravenous infusion of prostacyclin for arteriosclerosis obliterans 110 m or central retinal vein occlusion. 112 The mechanism of the fibrinolytic activity of prostacyclin is not known, but it does not depend on the endothelium. Although prostacyclin exhibits fibrinolytic action ex vivo, it shows no activity on euglobulin clots in vitro.
29 Of 10 prostanoids investigated, only 6-keto-PGE! had fibrinolytic activity in vitro.
29
u 3 The thrombolytic action of prostacyclin may therefore be a result of inhibition of the binding of fibrinogen to platelets 114 and the fibrinolytic action of a metabolite such as 6-keto-PGE,.
Even though the thrombolytic effect of prostacyclin is weaker and less general than that of streptokinase, 111 -113 prostacyclin potentiates streptokinase-induced thrombolysis in vivo. 116 Indeed, in human blood prostacyclin stimulates thrombolysis at concentrations that have no effect on hemostasis.
31
The vasodilator, platelet-suppressant, and thrombolytic properties of prostacyclin may all contribute to its beneficial therapeutic effect in patients with acute thrombotic episodes, such as retinal vein occlusion or sudden deafness of vascular origin. 112 However, these properties of prostacyclin cannot account for its proven therapeutic efficacy in patients with chronic peripheral vascular disease associated with tissue ischemia, such as arteriosclerosis obliterans or Raynaud's phenomenon. 117 -118 Clinicians began to discuss an ill-defined metabolic protection by prostacyclin against ischemic injury of affected limbs. Later, they borrowed the term cytoprotection from Andr6 Robert, 119 who coined it to describe the ability of several prostaglandins (including prostacyclin 120 ) to protect the gastric mucosa from damage by noxious agents. Recently, the term cellular protection has been proposed for the protective effects of prostacyclin in vitro 121 and histoprotection for the protection of tissues in vivo. Indeed, in vitro, prostacyclin protects platelets against deterioration, 122 126 is intensified by heparin in a way that is not understood.
Among the possible mechanisms underlying the histoprotective action of prostacyclin, the most interesting proposal is that prostacyclin in some way neutralizes the damaging oxygen free radicals generated in the ischemic area 127 on reperfusion. 127 - 131 These free radicals may derive from several sources. Certainly, in the heart, neutrophils that infiltrate the ischemic myocardium 127 may generate oxygen free radicals as a result of activation of their nicotinamide adenine dinucleotide phosphate (NADPH)-dependent membrane oxidase or their metabolism of AA. 46 The ischemic myocardium itself can also produce oxygen free radicals, either as a result of interconversion of xanthine dehydrogenase to xanthine oxidase with a concomitant massive decomposition of ATP to hypoxanthine 49 136 protect against hypoxic or ischemic injury to mitochondria, cells in culture, perfused isolated heart, or infarcted myocardium in vivo. The protective action of ubiquinone may be achieved through coupling the nucleotide dehydrogenases with the cytochrome oxidase system in the inner mitochondrial membrane 132 or, simply, by quenching superoxide anions, 132 whereas superoxide dismutase enzymically destroys superoxide anions. 49 - 136 One suggestion is that prostacyclin or its stable metabolites (e.g., 6-keto-PGE, 27 or stable metabolite X, 29 but not 6-keto-PGF lo 127 ) act as a replacement for ubiquinone in the CoQi 0 -deficient ischemic cardiac mitochondria. 132 Prostacyclin was first used clinically in 1979 to improve the circulation in patients with severe peripheral vascular disease, 137 and since then many possible therapeutic uses have been tested. Intravenous infusion for 6 hours a day for 4 or more days seems to be the optimal regimen in the treatment of vascular deficiencies 138 brought about by atherosclerosis 139 - 140 or vasoconstriction (as in Raynaud's phenomenon). 141 In 30 to 40% of the treated patients the ensuing beneficial effects last for several weeks or months. 142 Although a multicentered clinical trial 143 failed to show activity of prostacyclin in reducing the acute damage of myocardial infarction, there are clear-cut and important beneficial effects in preventing an early extension of the infarct. 144 Another area of potential therapeutic and diagnostic importance is in primary pulmonary hypertension. Studies of both children and adults with primary pulmonary hypertension 143 show a more than 20% fall in pulmonary vascular resistance in approximately 70% of patients treated with intravenous prostacyclin. Pulmonary hypertension that results from mitral stenosis, 146 chronic lung disease, 147 congestive heart failure, 148 -149 or adult respiratory distress syndrome 150 has also been improved by prostacyclin. Higenbottam 151 showed that continuous infusions of prostacyclin for up to 2 years allowed patients with severe pulmonary hypertension to live independently while awaiting a heartlung transplant. The beneficial hypotensive effects in the pulmonary circulation are clearly due to vasodilation, for they rapidly reverse when the infusion is stopped. In addition, Rubin et al. 132 advocate the use of prostacyclin as an aid in diagnosing the disease. Recent reviews on the clinical uses of prostacyclin are provided by Moncada and Vane, 153 160 The generation of 15-HPETE and 15-HETE by vascular cells was claimed to occur through cooxidation since the biosynthesis of hydroxy-lipids together with that of prostacyclin was inhibited by aspirin and indomethacin. 156 -157 On the other hand, there were claims that in human 161 and in calf 162 vascular cells the generation of prostacyclin is only partially 161 inhibited by indomethacin, if at all. 162 In further studies, 12-HETE and other monohydroxylated derivatives of AA were isolated from human, 161 rabbit, 163 and rat 164 blood vessels. The origin of hydroxylated lipids and the preferential routes for their oxygenation within the vascular wall remain an interesting area for investigation. Some of these lipoxygenase products could be involved in cell adhesion 165 and formation of new capillaries during angiogenesis. 166 Pretreatment of cultured endothelial cells with nordihydroguaiaretic acid (NDGA) or eicosatetreynoic acid (ETYA) decreased adherence of neutrophils. 165 Both of these substances inhibit lipoxygenase, but the selectivity (especially of NDGA) has been questioned. Also, both NDGA and ETYA, but not indomethacin, reduced proliferation and DNA synthesis of endothelial cells in culture. 166 When endothelial cells are stimulated to produce prostacyclin, hydroxyeicosatetraenoic acids (mainly 15-HETE) 156 l57 -16I~163 are formed that intensify the thrombogenic properties of the endothelial surface.
3 - 167 On the other hand, all of the products of lipoxygenation of arachidonic and linoleic acids (e.g., 15-HETE, 9-HODE, and 13-HODE) inhibit activation of rabbit platelets. 168 
13-HODE
In 1985, Buchanan and his colleagues 167 announced that monolayers of human cultured endothelial cells, in addition to the membrane-related production of prostacyclin, also synthesized a cytosol-associated lipoxygenase metabolite, which they called LOX. Inhibition of the generation of LOX (by 50 fiM sodium salicylate, incubated for 30 minutes) stimulated the production of prostacyclin and, conversely, an inhibition of the biosynthesis of prostacyclin (by 50 /i.M aspirin, incubated for 5 minutes) increased the generation of LOX. Under either condition, platelet adhesion to cultured endothelial cells was suppressed. However, when endothelial cells were incubated with aspirin (50 /xM for 30 minutes, with the assumed formation of salicylate), then the generation of prostacyclin and of LOX was substantially reduced and an enhancement of platelet adhesion to the endothelial cells was observed. Thus, it was suggested that endothelial cells generate a cyclooxygenase metabolite (prostacyclin) and a lipoxygenase metabolite, both of which have the property of increasing the thromboresistance of the endothelium.
In another paper by the same group 3 LOX was identified by high performance liquid chromatography and gas chromatography plus mass spectrometry as 13-HODE, a product of linoleic acid (18: 2n-6). Unstimulated human endothelial cells contained more than 3 /ig per 10* cells, and there was rather less in smooth muscle cells or fibroblasts. Concentrations of 13-HODE were decreased by thrombin or calcium ionophore, and none was detected after trypsin. When 13-HODE was bound to plastic, adhesion of platelets was decreased.
In a later paper, 169 the concentrations of 13-HODE found in endothelial cells were many orders less (17 ng/10* cells) and these were suppressed by addition of 10 /iM linoleic acid but stimulated by 25 or 50 fiM. linoleic acid. Exogenous 13-HODE had no effect on platelet binding to endothelial cells, leading to the suggestion that 13-HODE has an antiadhesive effect from inside the cell.
Much of this work remains to be confirmed and, in particular, it is important to show that increased production of 13-HODE stimulated by linoleic acid reduces platelet adhesion and to confirm the assumption that salicylate (but not aspirin) is a selective inhibitor of peroxidase activity, thereby preventing generation of 13-HODE.
The aforementioned in vitro data are in accordance with a reversal of the antithrombotic action of aspirin by salicylate and with the thrombogenic effects of high doses of aspirin in vivo. 170 This concept, however, is difficult to reconcile with the unknown fate of 13-hydroperoxyoctadecadienoic acid (HPODE), which presumably accumulates inside endothelial cells following treatment with salicylate.
It is surprising that, unlike 15-HETE, 13-HODE is not released into the medium from cultured endothelial cells and its antiadhesive action is said to be exerted from inside the cell. In cultured endothelial cells, the release of prostacyclin 65 is enhanced by thrombin, trypsin, and calcium ionophore A23187. However, all of these stimulators of phospholipases reduce rather than increase the generation of 13-HODE. The phosphatidylinositol in endothelial cells is poor in linoleic acid. 3 Thus, phospholipase C also does not seem to supply the substrate for the biosynthesis of 13-HODE.
According to the hypothesis of Buchanan et 171 As discussed earlier, 15-HETE intensifies the thrombogenic properties of endothelial cells, but like 9-HODE and 13-HODE, it inhibits activation of rabbit platelets. The balance between lipoxygenase-derived eicosanoids and octadecanoids generated by endothelial cells 172 depends on supplies of substrates and on whether the cell is activated or quiescent.
Exogenous 13-HODE has also been shown to increase prostacyclin production by fetal bovine aortic endothelial cells 173 and to inhibit thrombininduced thromboxane B 2 , with a concomitant increase in 12-HETE production in human platelets. 174 The 13-HODE story is further complicated by the observation that bovine aortic endothelial cells do not make 13-HODE. Rabbit endothelial cells do, but the concentration of extractable 13-HODE increases several hundredfold with time, an accumulation that is not inhibited by aspirin, salicylate, or known lipoxygenase inhibitors such as ETYA or NDGA. It is, however, inhibited by superoxide dismutase. This suggests that 13-HODE in these endothelial cells is a product of autolysis. 173 Endothelial cells are not the only ones in the circulation that have the ability to generate 13-HODE. Porcine neutrophils contain a lipoxygenase that, in a partly purified form, converts linoleic acid (18:2n-6) to 13-HODE at a rate twice as high as it converts AA (20:4n-6) to 12-HETE or 5-HETE to 5,12-di-HETE. The biochemical characteristics of this neutrophil lipoxygenase are quite different from those of platelet 12-lipoxygenase. 176 The biological role played by 13-HODE in neutrophils remains unknown. In epithelial cells, linoleic acid, after its transformation to O-acyl ceramide and to other unusual very-long-chain unsaturated lipids, 177 seems to act as a key factor in the maintenance of the water barrier in the epidermis. 178 -l79 There is evidence that linoleic acid is carried by these lipids into the stratum compactum of the epidermis where linoleic acid is converted by lipoxygenases to a series of lipid hydroperoxides. It may be that the latter are responsible for the proper differentiation of the epidermal cells into an effective stratum compactum and a horny layer. 178 -179 Clearly, endothelial and other cells have a varied capacity to produce prostacyclin, thromboxane A 2 , PGEj, PGD 2 , PGF 2 , 15-HETE, 12-HETE, 5-HETE, 13-HODE, various lipid hydroperoxides, lipid epoxides, leukotrienes, lipoxins, and perhaps 6-keto-PGE,. This plethora of putative mediators, probably generated in a continuously fluctuating way, makes it more and more difficult to visualize a unified system. Can we identify the main characters within this crowd of biologically active lipids? The antiaggregatory and antiadhesive prostacyclin and perhaps 13-HODE, made by endothelial cells, set against the proaggregatory and adhesive thromboxane A 2 and perhaps 12-HETE, made by platelets, form a scheme for a feasible and testable working hypothesis for the control of hemostasis in the circulation. However, lipid derivatives are only part of the story, as is seen in the next section.
Endothelium-Derived Relaxing Factor Generation of EDRF
EDRF is a labile vasodilator with a half-life counted in seconds. The generation of EDRF by endothelial cells is unaffected by cyclooxygenase inhibitors such as aspirin and indomethacin. This allows for an easy differentiation between EDRF and prostacyclin.
EDRF was discovered by Furchgott and Zawadzki, 5 who showed that the presence of the endothelial lining is obligatory for the vasorelaxant action of acetylcholine (ACh) on aortic and arterial strips or rings isolated from rabbits. We now know that when the endothelium is removed from vascular preparations of numerous species, ACh, at concentrations of 0.01 to 1.0 /iM, has no vasorelaxant action and often evokes contraction of the naked vascular smooth muscle at high concentrations of 10 to 100 fiM. Thus, the activation of muscarinic receptors 3 on endothelial cells triggers the generation of a diffusible and transferable substance that relaxes vascular smooth muscle-hence, the name
EDRF. iSom
Other substances that release EDRF from endothelial cells include bradykinin, 181 180 and electrical field stimulation 192 also release EDRF, and more of it is formed in arteries than in veins. 193 Interestingly, most of these stimulants also release prostacyclin, an important point to which we shall be returning. In the arterial wall, prostacyclin is produced by both endothelial and smooth muscle cells 64 -63 whereas EDRF is formed only by endothelial cells. Entry of extracellular calcium through calcium channels in the endothelial cell membrane does not seem to be part of the release mechanism. 194 On the other hand, a rise of intracellular free calcium is probably a prerequisite for release. 193 This may be linked to a sodium-calcium exchange mechanism 194 -196 or a calcium-activated potassium channel. 197 Intracellular events that link receptor stimulation to the release of EDRF include the activation of a guanosine 5'-triphosphate-regulatory protein and the increased breakdown of a phosphoinositide. 198 Diacylglycerol activation of protein kinase C is also involved since phorbol esters inhibit EDRF release. 199 -™ In rabbit aortic strips, basal EDRF release was not affected by inhibitors of mitochondrial ATP generation, whereas stimulated release of EDRF was inhibited. 201 -202 Thus, the mechanism underlying basal production seems different from that for stimulated release.
Actions of EDRF
Vascular smooth muscle is the obvious target for the biological action of EDRF. However, EDRF also potently inhibits platelet aggregation 203 and adhesion. 204 -M3 These effects are mediated by an increase in intracellular cyclic guanosine 3',5'-monophosphate (cGMP). Adenylate cyclase is stimulated by /3-adrenergic receptor agonists 206 and by prostacyclin 102 whereas the soluble guanylate cyclase of smooth muscle cells and platelets is stimulated by nitrovasodilators, including glyceryl trinitrate (GTN, nitroglycerin) 207 -a* and by EDRF. 209 -21°A t least two forms of phosphodiesterase are present in vascular smooth muscle to destroy cyclic nucleotides. One of them prefers cGMP to cAMP, is activated by a calcium/calmodulin complex, 206 and is selectively inhibited by 2-o-propoxyphenyl-8-azopurine-6-one (M & B 22948). This phosphodiesterase inhibitor potentiates selectively GTNinduced and EDRF-induced relaxation of vascular smooth muscle strips 210 and inhibition of platelet aggregation. 211 This reinforces the idea that cGMP is the second messenger for the actions of EDRF and points to a similarity between the mode of action of EDRF and GTN.
That EDRF is a local chemical messenger was demonstrated by a "sandwich" arrangement of two rabbit aortic strips, one with endothelium and the other without. 180 This showed a transfer of EDRF from the endothelium of the first strip to the smooth muscle of the second. Similarly, luminal perfusion of arteries with endothelium demonstrated transfer of EDRF to an endotheliumdenuded arterial detector.
212 -213 -2 " 3 The endothelial lining of the preconstricted coronary arteries of isolated rabbit hearts generated EDRF in response to stimulation with ACh 216 or with activated platelets. 217 In dogs, EDRF appears to mediate the ACh-induced vasodilation of the femoral artery 218 and of cerebral arterioles. 219 In pentobarbital-anesthetized dogs, increased blood flow in the femoral artery caused flow-dependent dilation. This response was abolished by removal of the endothelial cells 220 or perfusion with methylene blue, but not by indomethacin. 221 Release of EDRF has also been demonstrated in the iliac and epicardial arteries of conscious dogs 222 -223 and in arterioles on the brain surface of anesthetized mice. 224 In rats, an increase in gastric mucosal blood flow induced by ACh or by vagal stimulation was said to be EDRF-mediated. 223 These data obtained in v i VO 218-226 are j n a c c O rd with the concept that endothelial production of EDRF provides the vascular wall with a shield against the vasospasm brought about by vasoconstrictors released from activated platelets. 227 Does EDRF (or the lack of it) play a role in cardiovascular disease? The aforementioned findings confirm the view that endothelial injury leading to a lack of EDRF may reverse the indirect vasodilator action to a direct vasoconstrictor action of a number of endogenous vasoactive mediators, 228 even in arteries as small as 150 jxm in diameter. 229 Segments of human blood vessels, including coronary and pulmonary arteries as well as isolated perfused umbilical arteries and veins, release EDRF. 184 -23°-232 Damage to the endothelium of pulmonary arteries could therefore lead to the loss of EDRF and the development of pulmonary hypertension. Arterial strips from rats with genetic, renal, mineralocorticoid or coarctation hypertension, as well as from salt-sensitive Dahl rats, relaxed less effectively to ACh, A23187 and histamine. 233 -236 Rabbits, in which a ligature had been placed round the abdominal aorta, lost sensitivity to the relaxant effects of ACh and A23187 in their hypertensive thoracic but not their normotensive abdominal vessels. 237 Coronary arteries of anesthetized dogs subjected to brief periods of hypertension constricted more to 5-hydroxytryptamine than those that had not been so treated. 238 In all instances, relaxation responses to direct vasodilators were not affected even though hypertension caused some thickening of the intimal layer of the blood vessels.
Endothelium-dependent relaxation is impaired in arteries from hypercholesterolemic rabbits 239 In cholesterol-fed rabbits, the attenuation of EDRFmediated responses occurred without any evidence of damage to the endothelial lining. Perfused hind limbs of cholesterol-fed rabbits in vivo showed reduced responses to ACh but not to the directly acting vasodilator sodium nitroprusside. 245 EDRF-mediated responses of monkeys increased to normal when their atherogenic diet was replaced by standard feed. 246 This change of diet also resulted in regression of the atherosclerosis. The vascular intimaJ layer remained abnormally thickened, so the reduced responses could not have been due to an increased diffusion distance between the endothelium and smooth muscle. 246 It is interesting that endothelium-dependent relaxations of porcine coronary arteries could be facilitated by adding cod-liver oil to their diet. 247 In humans, an intracoronary infusion of ACh resulted in vasodilation of healthy arteries and vasoconstriction of their stenotic atherosclerotic branches. 226 Also, coronary arteries from patients who had undergone heart transplantation, which are prone to atherosclerosis, either failed to dilate or paradoxically constricted to ACh. 248 Reduced endothelium-dependent relaxations were again seen in isolated aortas from old rats 249 and in pig coronary arteries made spastic by denudation of the endothelium 3 months previously. 250 Even slight damage to the endothelium can affect the formation of EDRF, for pial arterioles of anesthetized cats injured by a combination of mercury light and fluorescein dye lost their relaxant responses to ACh and bradykinin. 251 This type of damage reverses after an hour and the endothelium becomes responsive again. 252 Reduced EDRF activity during subarachnoid hemorrhage may contribute to cerebral vasospasm, since cerebrospinal fluid from such patients 233 inhibited relaxations of isolated dog arteries to A23187. This was due to contamination of the cerebrospinal fluid with hemoglobin, which blocks the activity of EDRF.
The nitrovasodilators share nitric oxide (NO) as a final common pathway, for NO acts directly to activate the soluble guanylate cyclase of smooth muscle cells. NO can be liberated directly from organic nitrates in the presence of thiols such as cysteine. 254 Formation of NO from sodium nitroprusside and from SIN-1 (a metabolite of molsidomine) occurs spontaneously by a thiol-independent mechanism. 254 Methylene blue inhibits the activation of guanylate cyclase by NO and SIN-1, partially by GTN, but not by sodium nitroprusside. 255 In contrast, hemoglobin 206 -207 inhibits the vasorelaxant action of NO, SIN-1, GTN, and sodium nitroprusside. Hemoglobin is a direct inhibitor of the active ferroheme center of guanylate cyclase 256 and also effectively removes NO from solution. 257 The vasorelaxant actions of EDRF are antagonized by both methylene blue and hemoglobin. 212 Since activation of guanylate cyclase is common to both GTN and EDRF, this justifies the use of the nickname endogenous nitroglycerin for EDRF. The similarity is further emphasized since tissues made tolerant to the relaxant effects of GTN fail to respond to EDRF. 258 EDRF is one of the few endogenous mediators that exerts its physiological actions by activation of the soluble guanylate cyclase of smooth muscle cells. 259 . Removal of the endothelium results in a 70% reduction of smooth muscle cyclase activity 260 together with some loss of reactivity to nitrovasodilators. 261 
Structure of EDRF
The chemical structure of EDRF has been investigated intensely. The search was complicated by its short half-life and by the use of whole-artery preparations, which did not allow distinction between inhibition of the generation of EDRF, of its activity, or changes in its inactivation.
Many attempts have been made to implicate a metabolite of AA, either arising from cyclooxygenation phenylhydrazine, potassium borohydride, dithiothreitol, cysteine, SKF 525A, 267 and metyrapone. 268 Studies carried out with cultured endothelial cells have given new insight into the chemical structure and properties of EDRF, because the EDRF generators (endothelial cells) and the EDRF detectors (vascular strips deprived of endothelium) were separated. Aortic endothelial cells were cultured on microcarrier beads, packed in columns, and perfused with oxygenated nutrient fluid. The effluent from the column superfused either a single vascular strip 269 -"o-z 7 • or several vascular strips 21 arranged in a Vane cascade. 272 With this technique, the humoral character of EDRF and its instability, with a half-life in Krebs-Ringer solution of 30 to 45 seconds and in the bioassay cascade of 6 seconds, was confirmed. 21 This technique also allowed the study of the mode of action of inhibitors and potentiators of EDRF 273 -274 as well as the collection, separation, and analysis of the EDRF-containing effluent. Unfortunately, cells cultured on beads were generally insensitive to most EDRF releasers except bradykinin and ionophore A23187.
-269
Superoxide dismutase 273 and ferricytochrome c 274 reveal the spontaneous release of EDRF from endothelial cells, potentiate the stimulated release, and antagonize the inactivation of EDRF by ferrous ions. Since ferrous ions generate superoxide anions in oxygenated buffers, 49 the simplest interpretation of the aforementioned results is that EDRF is destroyed by O 2~ whereas scavengers of O 2~ (superoxide dismutase and ferricytochrome c) protect EDRF from destruction. Many of the EDRF "inhibitors" that we listed may partially act by generating O 2~, since their activity is considerably attenuated by superoxide dismutase or ferricytochrome c. 274 Some of these results and an analogy between the mechanisms of stimulation of guanylate cyclase by EDRF 21   -212 and GTN  212 led Khan and Furchgott   275 and Ignarro et al. 276 to speculate that EDRF was NO. Indeed, recent studies show that EDRF released from cultured porcine endothelial cells 277 is NO or a chemically related radical. EDRF released from perfused cultured endothelial cells by bradykinin 21 or NO gas dissolved in deoxygenated water both relaxed the bioassay cascade of vascular smooth muscle in a dose-dependent manner. The relaxation induced by EDRF or NO declined at the same rate (W2 ~4 seconds) during passage down the isolated tissue cascade. 272 The actions of both EDRF and NO were inhibited by hemoglobin (which binds NO) 257 and potentiated by superoxide dismutase. 273 Superoxide anions must, therefore, contribute to the inactivation of both substances. Finally, NO was assayed chemically as the chemiluminescent product of its reaction with ozone. NO was released from porcine endothelial cells by bradykinin in amounts that accounted for the actions of EDRF, showing that this EDRF was identical to NO. 277 EDRF released from endothelial cells of bovine pulmonary artery and vein by ACh or bradykinin also behaved chemically like NO. 278 This EDRF produced identical shifts in absorption spectrum peaks to genuine NO during its reaction with hemoglobin.
EDRF from porcine aortic endothelial cells and NO gas have also been tested on platelet aggregation. The antiaggregatory activity of both 211 was potentiated by superoxide dismutase and the selective inhibitor of cGMP phosphodiesterase, M & B 22948, and inhibited by hemoglobin and Fe 2+ . Moreover, there was synergism 279 between the antiaggregatory effect of prostacyclin and subthreshold concentrations of EDRF or NO. In addition to inhibiting human platelet aggregation, EDRF (NO) released from cultured bovine aortic endothelial cells by bradykinin reduced the adhesion of platelets to endothelial cells. 204 -Ŵ e have also used bovine aortic endothelial cells grown on microcarrier beads and perfused with Krebs-Ringer solution to investigate the release of EDRF. 200 EDRF was bioassayed on a cascade of four strips of rabbit aorta and prostacyclin by radioimmunoassay of 6-keto-PGF la . Our cultures of endothelial cells released EDRF and prostacyclin when stimulated with bradykinin and its congeners, adenosine 5'-diphosphate, ATP, AA, or phospholipase C. The release of both EDRF and prostacyclin was inhibited by phorbol myristate acetate, a diacylglycerol kinase inhibitor (R59022), or gentamycin. Our results lead to the important concept that the receptor-mediated release of EDRF and prostacyclin are coupled and the initial common step is activation of a phospholipase C. 200 Our conclusion that activation of the same receptors ultimately leads to release of both EDRF and prostacyclin suggests that these substances act in concord as a common mechanism of defense for the endothelial cells. The synergism already shown between EDRF (NO) and prostacyclin 279 in preventing platelet activation might take on a new dimension if a similar synergism is demonstrated for other cells in the circulation. Interestingly, rat neutrophils generate a neutrophil-derived relaxing factor that relaxes smooth muscle, 280 and human neutrophils and mononuclear cells inhibit platelet aggregation by elaborating a factor indistinguishable from EDRF. 281 This factor even shows synergism with prostacyclin on platelet aggregation, 282 whereas there may not be synergism between the vasodilator effects of prostacyclin and EDRF on smooth muscle. 283 The concept that EDRF and NO are identical has been challenged. One group 284 claims that NO, but not EDRF, relaxes guinea pig teniae coli, and another 285 that tracheal smooth muscle relaxes to NO but not to EDRF. Nevertheless, the results are not consistent and the first group was unable to demonstrate relaxations of guinea pig trachea to either NO or EDRF. 284 Clearly, EDRF is a potent vasorelaxant of arterial smooth muscle and may not reliably relax other types of muscle. 286 -287 In addition, it is said that EDRF can be absorbed on to an anion exchange resin and NO cannot. 288 Finally, the elaboration of more than one EDRF has been postulated.
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Conclusions
The relative importance of prostacyclin, EDRF, and 13-HODE for homeostasis at the bloodendothelium interface in vivo remains to be elucidated. At present, we can offer only a working hypothesis.
Normally, the vascular endothelium remains thromboresistant because of a continuous basal release of minute amounts of prostacyclin and EDRF, possibly in response to pulsatile pressure. The role of 13-HODE requires further investigation. This basal release of prostacyclin and EDRF can be supplemented by an increased coupled release through receptor activation by 5-hydroxytryptamine or adenine nucleotides discharged from activated platelets. 290 In addition, a direct transfer of prostaglandin endoperoxides from platelets to the endothelium amplifies the release of prostacyclin. Prostacyclin and EDRF discourage platelets and leukocytes from sticking to the endothelial lining of blood vessels. Besides preventing platelet aggregation, EDRF and prostacyclin cause vasodilation and oppose the effects of platelet-derived vasoconstrictors ( Figure 3) .
A further stimulation of platelets, 291 levels, 295 or a hypertensive insult to the vascular wall. 219 White cells would begin to adhere to the endothelium in the form of mural white thrombi.
Local vasospasm or stenosis will follow the pathological interaction of activated white cells with arterial segments deprived of the prostacyclin-EDRF defensive mechanism. Thrombin formation will be initiated by platelet factors and by an interaction of plasma factors with subendothelial layers.
Thus, a local deficiency in prostacyclin and EDRF may underlie atherogenesis and thrombogenesis, with a subsequent stenosis of coronary, cerebral, and peripheral arteries manifested by angina pectoris, myocardial infarction, stroke, and ischemic ulcers. These diseases may be ameliorated by a compensatory overproduction of prostacyclin, EDRF, or t-PA in healthy arterial segments adjacent to a vasospastic or stenotic region or by pharmacological treatment with prostacyclin and its stable analogues, releasers of prostacyclin (e.g., derivatives of nicotinic acid or dazoxiben), nitroglycerinlike drugs, urokinase, streptokinase, or t-PA. When the combined effects of prostacyclin, EDRF, and t-PA increase blood flow to the ischemic organ, postischemic reperfusion damage may occur because of the generation of oxygen free radicals. We propose that this effect may be counteracted by the biotransformation of prostacyclin to cytoprotective metabolites such as 6-keto-PGE, or stable metabolite X, which, like superoxide dismutase, 296 may be cardioprotective due to the removal of O 2~.
We are aware of how hypothetical our description of these interactions among only three out of the many endothelial mediators is, especially since EDRF and 13-HODE are at such an early stage of exploration. However, the recent flood of data on the endothelium-dependent homeostatic mechanisms in the circulation has prompted us to try to bring some order into the growing amount of information.
Other Mediators
It is beyond the scope of this review to discuss factors such as platelet-derived growth factor, said to cause vasoconstriction, 297 t-PA, and others. However, at the time of writing, another important mediator released by the endothelial cells, endothelin, has been discovered and characterized.
14 Endothelin is a peptide of 21 amino acids, generated by endothelial cells through an unusual proteolytic processing. Levels of the messenger RNA that makes preproendothelin were increased by thrombin, calcium ionophore, and epinephrine-stimuli that also release the vasodilators prostacyclin and EDRF. The most striking property of endothelin, which is ten times more potent than angiotensin II as a vasoconstrictor, is the long duration of hypertensive action as demonstrated on rat blood pressure. After a single intravenous injection, the blood pressure was elevated for more than one hour. Moreover, the sensitivity of renal artery segments to endothelin was greater in spontaneously hypertensive rats than in Wistar-Kyoto rats. 298 In a survey of the actions of endothelin on vascular smooth muscle, we 299 found venous tissue to be more sensitive than arterial smooth muscle to endothelin.
Interestingly, endothelin also releases prostacyclin and EDRF, 300 and when given intravenously to anesthetized rats, the pressor activity is strongly limited by the action of these vasodilators. Indeed, when the basal blood pressure is high, intravenous endothelin may only cause a fall in blood pressure. Furthermore, endothelin is removed in the pulmonary circulation in vivo and in vitro 301 ; about 60% disappeared in one passage through isolated guinea pig lungs.
Our working hypothesis is that endothelin is a local hormone, released by the endothelial cells to constrict the underlying smooth muscle. The pressor activity of any endothelin released luminally into the circulation will be strongly ameliorated by removal in the lungs and by release of the vasodilators prostacyclin and EDRF.
The discovery of endothelin clearly adds a new dimension to the role of endothelial cells in disease states such as atherosclerosis and hypertension. References 
